On Monday, Bank of America (NYSE:BAC) (BofA) increased its price target on AbbVie (NYSE:ABBV) to $167 from $165, while maintaining... ByInvesting.com • Feb 05, 2024 Goldman Sachs raises AbbVie stock ...

AbbVie’s former CEO Richard Gonzalez—who collected a $25.7 million payout for his final full year on the job in 2023—often ranked among the industry’s highest-paid CEOs during his tenure.

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 29 trades. If we consider the specifics of each trade ...

The latest price target for AbbVie (NYSE:ABBV) was reported by Wells Fargo on March 5, 2025. The analyst firm set a price target for $240.00 expecting ABBV to rise to within 12 months (a possible ...

Our reporting shows this will be painful for many biopharma companies who rely on funds from the sale of PRVs. Speaking of money, AbbVie and Eli Lilly struck a pair of mid-size deals in hot spaces.

One of the last big phar­ma hold­outs in obe­si­ty has now en­tered what has be­come the most sought-af­ter field in the in­dus­try.

AbbVie ranked sixth on the list of largest biomedical companies by revenue. This stock is one of the top pharmaceutical stock picks across Wall Street and pays a dependable 3.25% dividend.

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist Gubra A/S. In addition, there will ...

AbbVie is joining the industry’s rush to develop new obesity medicines, announcing Monday a deal with Denmark-based Gubra to license a drug that could compete with experimental therapies being ...